As of late August, the Senate Committee on Finance had finished collecting an initial set of responses from pharmaceutical companies concerning educational grants but had not yet begun reviewing the responses; nor did it have a set timeline for finishing the review process. After going over the materials, the Committee will decide whether it will ask pharmaceutical companies for more detailed information and/or hold a hearing on the issue.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments